Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893045 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
A Phase 3 study of Iron Deficiency Anemia, sponsored by AMAG Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 15
- Study locations
NCT03893045: Recruiting Phase 3 study of Iron Deficiency Anemia, sponsored by AMAG Pharmaceuticals.
NCT03893045 is a Phase 3 study of Iron Deficiency Anemia that is actively recruiting participants, run by AMAG Pharmaceuticals. The registered enrollment target is 75 participants, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (61% lower). The trial reports 15 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03893045, a Phase 3 study of Iron Deficiency Anemia, is actively recruiting participants, sponsored by AMAG Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).
Primary Outcome
Proportion of subjects achieving a change in hemoglobin from Baseline to Week 5
Conditions Studied
Interventions
- DRUG Iron sucrose
- DRUG ferumoxytol
Study Locations (15)
Other
- JSC Saules seimos medicinos centras - Kaunas
- Klaipeda Children's Hospital - Klaipėda
- Children's Hospital-Affiliate of Vilnius University Hospital Santariskiu Klinikos - Vilnius
- Osrodek Badan Klinicznych In Vivo sp. z o.o. - Bydgoszcz
- Prywatny Gabinet Lekarski Dr N. med. Jerzy Brzostek - Dębica
- Pro Familia Altera Sp. z o.o. - Katowice
- Korczowski Bartosz, Gabinet Lekarski - Rzeszów
- Centrum Zdrowia MDM - Warsaw
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu - Wroclaw
Florida
- University of Florida - Gainesville
- Optimus U Corporation - Miami
- Biomedical Research LLC - Miami
Arkansas
- Arkansas Children's Hospital - Little Rock
Georgia
- Gwinnett Research Institute - Buford
Texas
- Sun Research Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2025-10 |
| Phase | Phase 3 |
What NCT03893045 shows while recruiting
NCT03893045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Iron sucrose is the first listed.
NCT03893045 lists 15 locations in 5 states (Other, Florida, Arkansas).
Frequently Asked Questions
What is clinical trial NCT03893045 about?
NCT03893045 is a clinical study titled "A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects". This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjec...
What is the current status of trial NCT03893045?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2019-09-18. Estimated completion is 2025-10.
What conditions does trial NCT03893045 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia.
What interventions are being tested in trial NCT03893045?
The interventions under investigation include: Iron sucrose (DRUG), ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT03893045?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03893045 being conducted?
This trial has 15 study locations across Arkansas, Florida, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03893045's enrollment target sits among peer trials
75 15th of 24 higher than 10 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
-
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
-
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI